New Dual-Release Levodopa Capsule Wins Expert Consensus for Parkinson’s Care

A panel of nine leading European Parkinson’s disease specialists has issued a set of consensus recommendations for integrating IPX203, a next-generation modified-release levodopa/carbidopa formulation, into routine clinical practice. The recommendations, published in the Journal of Neurology, arrive at a pivotal moment: the formulation, marketed as Hopledo, received approval in Europe in August 2026, following its 2024 approval by the United States Food and Drug Administration. The experts, drawn from Germany, Italy, Spain, France and Switzerland, collectively hold between 18 and 36 years of clinical experience and convened in person in September 2025 to define how the new therapy should be deployed among the growing population of patients whose symptoms are no longer smoothly controlled by standard oral medication.

The clinical problem the panel sought to address is one of the most familiar and frustrating in neurology. Levodopa remains the foundational treatment for the motor symptoms of Parkinson’s disease, but it is almost always given in combination with an inhibitor of dopa decarboxylase, such as carbidopa or benserazide, to prevent its breakdown outside the brain. Immediate-release formulations of this combination have a short half-life and are absorbed inconsistently, producing plasma levodopa concentrations that rise and fall with each dose. These fluctuations can emerge within two years of starting therapy and are a major, though not exclusive, driver of motor complications: delayed ON periods, unpredictable ON-OFF swings, end-of-dose wearing OFF and peak-dose dyskinesias, along with non-motor symptoms that erode quality of life. Patients often respond by taking doses ever more frequently, adding adjunctive drugs, and eventually facing the question of device-aided therapies such as deep brain stimulation or infusion pumps.

IPX203 was engineered specifically to flatten those pharmacokinetic peaks and troughs. Each capsule contains a mixture of immediate-release granules and extended-release pellets: the immediate-release component delivers the full carbidopa dose and 25 percent of the levodopa dose for rapid onset, while the remaining 75 percent of the levodopa is released gradually from pellets coated with sustained-release, mucoadhesive and enteric layers that promote absorption in the proximal small intestine. The design goal is to provide both a fast start and sustained plasma levodopa concentrations, reducing peak-to-trough variability and allowing less frequent dosing. In clinical studies, including the pivotal randomised phase 3 RISE-PD trial against immediate-release levodopa/carbidopa, the formulation increased Good ON time, defined as ON time without dyskinesia plus ON time with non-troublesome dyskinesia, significantly reduced OFF time and improved motor symptom control.

The consensus process itself was deliberately structured. The sponsor, Zambon Biotech SA, drafted eight initial statements grounded in current literature and unmet patient needs, which the board reviewed, voted on using a three-point scale, and then debated in a moderated roundtable. One statement was judged to fall outside the scope of the initiative because it did not centre on IPX203 and was dropped. The remaining statements were refined and re-voted, with final agreement levels ranging from 88.9 percent to 100 percent across seven topics covering the definition of motor symptom control, patient selection, positioning within the treatment pathway, switching strategies, and monitoring and follow-up.

On definitions, the panel reached unanimous agreement that motor complications in Parkinson’s disease should be understood as the combination of the number of motor fluctuations, the duration and severity of OFF time, and the presence and severity of dyskinesia as rated by the patient on the MDS-UPDRS part IV scale throughout the day. The experts stressed that motor fluctuations and dyskinesia are distinct phenomena that should not be conflated, and they flagged the exclusion of non-motor fluctuations, such as anxiety, pain and cognitive swings, as a gap, since these track closely with patients’ overall experience. They also debated the reliance on the patient-completed Hauser diary alone, calling instead for objective functional assessment and standardised severity ratings that blend patient and clinician perspectives. A second unanimous statement defined optimal motor control primarily as maximising Good ON time, though participants noted that the RISE-PD endpoint’s exclusion of freezing of gait, which affects roughly 38 to 65 percent of patients depending on disease duration, may yield an incomplete picture of treatment efficacy.

Perhaps the most consequential recommendation concerns who should receive the drug and when. The panel agreed unanimously that IPX203 should be considered for patients experiencing motor fluctuations who remain inadequately controlled even on an optimised levodopa/carbidopa regimen, and it pushed back against the idea that the formulation is a late-stage rescue therapy. Instead, the experts argued it should be viewed as a viable and earlier option in the optimisation process, potentially a first-line choice for managing motor fluctuations once initial levodopa dosing has been refined. They acknowledged, however, that RISE-PD enrolled patients with advanced disease, so broader use in earlier stages will require real-world evidence or further studies. Although the product label does not include an OFF-time threshold, the panel noted that the trial’s inclusion criterion of at least 2.5 hours of daily OFF time, along with the so-called 5-2-1 rule, levodopa taken five or more times per day, at least two hours of OFF time daily, and at least one hour of troublesome dyskinesia, offers practical benchmarks for identifying candidates.

The panel also addressed the drug’s relationship with device-aided therapies, though with the lowest agreement of any statement at 88.9 percent. IPX203 should be positioned as an oral optimisation strategy that can be used before deep brain stimulation, magnetic resonance-guided focused ultrasound or pump-based therapies, potentially serving as a bridge for patients not yet ready or indicated for invasive procedures, or as an alternative for those unwilling or unsuitable to undergo them. The experts were careful to say that the current evidence base is not mature enough to conclude that IPX203 can meaningfully delay the need for such interventions: the nine-month open-label extension of RISE-PD provides encouraging signals, but longer-term prospective and real-world data are required. They emphasised that the drug should be one option within a therapeutic sequence rather than a mandatory step, preserving patient choice and shared decision-making, and they preferred the phrase person with Parkinson’s disease with motor complications over the ambiguous label advanced PD.

Practical switching questions received detailed attention, particularly the combination of IPX203 with catechol-O-methyltransferase inhibitors. COMT inhibitors were excluded from RISE-PD because, by blocking the conversion of levodopa into the inactive metabolite 3-O-methyldopa, they alter levodopa metabolism and would have confounded the trial’s pharmacokinetic analysis. The panel unanimously agreed that this exclusion does not mean the combination cannot be used in practice, but it warned that no safety or efficacy data on the pairing currently exist. Because COMT inhibitors increase levodopa bioavailability and prolong its half-life, combining them with IPX203’s sustained-release profile could raise peak plasma levodopa concentrations in some cases, for example with opicapone, increasing the risk and severity of dyskinesia. Differences in dosing frequency add further complexity, and the experts called for phase 4 trials or real-world evidence to guide dose adjustments.

On monitoring, the group unanimously recommended that initial follow-up after conversion be based on patient response and tolerability, with subsequent visits guided by clinical need rather than a fixed schedule. They judged pre-scheduled visits within the first few days of switching unfeasible in busy practices and instead favoured patient-initiated contact, supported by comprehensive education covering expected adverse events, recognition of problems requiring clinic contact, management of overdosing and increased fluctuations, and instructions for tapering or re-titration during the first one to two weeks. Structured support through nurse-led assistance, phone or digital communication channels and trained staff was seen as essential to keep minor issues from falling back on physicians.

The panel closed with a wide-ranging research agenda and a communication strategy aimed at both patients and general neurologists, who manage a large share of people with Parkinson’s across Europe. Open questions include whether IPX203 can prevent motor fluctuations by acting at the synaptic level, its long-term effects on dyskinesia, non-motor symptoms, night-time akinesia, early morning ON status, orthostatic hypotension and freezing of gait, and how to distinguish good from poor levodopa absorbers. The experts also urged clinicians to confront levodopa phobia, the misplaced fear that levodopa is neurotoxic or loses effectiveness over time, and to explain that IPX203’s higher nominal levodopa dose is designed to sustain exposure rather than raise peak concentrations. Patients should be told the onset may be slightly slower than immediate-release levodopa, that high-fat meals may delay absorption, and that capsule contents can be sprinkled on applesauce for those with swallowing difficulties. With clear education, practical conversion tools and collaboration with neurological societies, the panel concluded, the formulation could meaningfully increase mobility and reduce treatment burden for patients living with motor fluctuations.

Subject of Research: Consensus recommendations for integrating the modified-release levodopa/carbidopa formulation IPX203 into the management of motor fluctuations in Parkinson's disease

Article Title: Consensus-based perspectives on integrating IPX203 into Parkinson’s disease management

Article References: Höglinger, G., Buhmann, C., Ebersbach, G., Fabbri, M., Kägi, G., Pagonabarraga, J., Santos García, D., Tessitore, A., & Tinazzi, M. (2026). Consensus-based perspectives on integrating IPX203 into Parkinson’s disease management. Journal of Neurology, 273(11), Article 656. https://doi.org/10.1007/s00415-026-14186-1

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14186-1

Keywords: Parkinson's disease, IPX203, levodopa, carbidopa, motor fluctuations, dyskinesia, modified-release formulation, RISE-PD trial, device-aided therapies, deep brain stimulation, COMT inhibitors, clinical consensus